Uncategorized
Aerie reports $25.8 million net loss in first quarter
Aerie Pharmaceuticals reported a GAAP net loss of $25.8 million, or $0.76 per share, in the first quarter of 2017, compared with $22.7 million, or $0.85 per share, in the same quarter of 2016.Operating expenses were reported at $25.4 million, with $10.9 million in research and development expenses and $14.5 million in selling, general and administrative expenses, according to a company press release. Operating expenses totaled $22.1 million in the first quarter of 2016.